The elimination of damaged cell components is essential for the maintenance of the body’s tissues and organs.
Novartis reportedly in talks to buy MorphoSys; Astellas cuts PhII program; Silence’s $120M private placement
Plus, news about Adverum, BridgeBio Pharma, Vaxcyte, Corbus and Immunocore: Novartis reportedly in deal talks with MorphoSys: The Swiss Big Pharma is in advanced talks